125 related articles for article (PubMed ID: 38289674)
1. Evaluating end-to-end continuous antibody manufacture with column-free capture alternatives from economic, environmental, and robustness perspectives.
Neves CPG; Coffman JL; Farid SS
Biotechnol Prog; 2024 Jan; ():e3427. PubMed ID: 38289674
[TBL] [Abstract][Full Text] [Related]
2. Integrated continuous bioprocessing: Economic, operational, and environmental feasibility for clinical and commercial antibody manufacture.
Pollock J; Coffman J; Ho SV; Farid SS
Biotechnol Prog; 2017 Jul; 33(4):854-866. PubMed ID: 28480535
[TBL] [Abstract][Full Text] [Related]
3. Optimising the design and operation of semi-continuous affinity chromatography for clinical and commercial manufacture.
Pollock J; Bolton G; Coffman J; Ho SV; Bracewell DG; Farid SS
J Chromatogr A; 2013 Apr; 1284():17-27. PubMed ID: 23453463
[TBL] [Abstract][Full Text] [Related]
4. End-to-end continuous bioprocessing: Impact on facility design, cost of goods, and cost of development for monoclonal antibodies.
Mahal H; Branton H; Farid SS
Biotechnol Bioeng; 2021 Sep; 118(9):3468-3485. PubMed ID: 33792918
[TBL] [Abstract][Full Text] [Related]
5. Fed-batch and perfusion culture processes: economic, environmental, and operational feasibility under uncertainty.
Pollock J; Ho SV; Farid SS
Biotechnol Bioeng; 2013 Jan; 110(1):206-19. PubMed ID: 22806692
[TBL] [Abstract][Full Text] [Related]
6. Process economics evaluation of cell-free synthesis for the commercial manufacture of antibody drug conjugates.
Stamatis C; Farid SS
Biotechnol J; 2021 Apr; 16(4):e2000238. PubMed ID: 33231912
[TBL] [Abstract][Full Text] [Related]
7. Transfer of a three step mAb chromatography process from batch to continuous: Optimizing productivity to minimize consumable requirements.
Gjoka X; Gantier R; Schofield M
J Biotechnol; 2017 Jan; 242():11-18. PubMed ID: 27939321
[TBL] [Abstract][Full Text] [Related]
8. Biomanufacturing evolution from conventional to intensified processes for productivity improvement: a case study.
Xu J; Xu X; Huang C; Angelo J; Oliveira CL; Xu M; Xu X; Temel D; Ding J; Ghose S; Borys MC; Li ZJ
MAbs; 2020 Jan; 12(1):1770669. PubMed ID: 32425110
[TBL] [Abstract][Full Text] [Related]
9. Feasibility of using continuous chromatography in downstream processing: Comparison of costs and product quality for a hybrid process vs. a conventional batch process.
Ötes O; Flato H; Winderl J; Hubbuch J; Capito F
J Biotechnol; 2017 Oct; 259():213-220. PubMed ID: 28684321
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of continuous nonaffinity capture chromatography for a recombinant enzyme-optimization for a changing perfusion feedstream and comparison to batch processing.
Thompson C; Wilson K; Larkin C; Lee J; Wang WK; Wendeler M
Biotechnol Prog; 2018 Sep; 34(5):1195-1204. PubMed ID: 30094961
[TBL] [Abstract][Full Text] [Related]
11. Decisional tool for cost of goods analysis of bioartificial liver devices for routine clinical use.
Mendonça da Silva J; Stamatis C; Chalmers SA; Erro E; Selden C; Farid SS
Cytotherapy; 2021 Aug; 23(8):683-693. PubMed ID: 34116945
[TBL] [Abstract][Full Text] [Related]
12. Continuous countercurrent tangential chromatography for mixed mode post-capture operations in monoclonal antibody purification.
Dutta AK; Fedorenko D; Tan J; Costanzo JA; Kahn DS; Zydney AL; Shinkazh O
J Chromatogr A; 2017 Aug; 1511():37-44. PubMed ID: 28697935
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. A new, integrated, continuous purification process template for monoclonal antibodies: Process modeling and cost of goods studies.
Xenopoulos A
J Biotechnol; 2015 Nov; 213():42-53. PubMed ID: 25959171
[TBL] [Abstract][Full Text] [Related]
15. GMP implementation of a hybrid continuous manufacturing process for a recombinant non-mAb protein-A case study.
Natarajan V; Soice N; Mullen J; Bull D
Biotechnol Prog; 2024 Mar; ():e3459. PubMed ID: 38553839
[TBL] [Abstract][Full Text] [Related]
16. Economic assessment of continuous processing for manufacturing of biotherapeutics.
Gupta P; Kateja N; Mishra S; Kaur H; Rathore AS
Biotechnol Prog; 2021 Mar; 37(2):e3108. PubMed ID: 33305493
[TBL] [Abstract][Full Text] [Related]
17. Economic Analysis of Batch and Continuous Biopharmaceutical Antibody Production: A Review.
Yang O; Qadan M; Ierapetritou M
J Pharm Innov; 2019; 14():1-19. PubMed ID: 30923586
[TBL] [Abstract][Full Text] [Related]
18. Process economics evaluation and optimization of adeno-associated virus downstream processing.
Lyle A; Stamatis C; Linke T; Hulley M; Schmelzer A; Turner R; Farid SS
Biotechnol Bioeng; 2023 Apr; ():. PubMed ID: 37086200
[TBL] [Abstract][Full Text] [Related]
19. Integrated continuous biomanufacturing platform with ATF perfusion and one column chromatography operation for optimum resin utilization and productivity.
Kamga MH; Cattaneo M; Yoon S
Prep Biochem Biotechnol; 2018 May; 48(5):383-390. PubMed ID: 29509101
[TBL] [Abstract][Full Text] [Related]
20. A Direct Approach for Process Development Using Single Column Experiments Results in Predictable Streamlined Multi-Column Chromatography Bioprocesses.
Utturkar A; Gillette K; Sun CY; Pagkaliwangan M; Quesenberry R; Schofield M
Biotechnol J; 2019 Apr; 14(4):. PubMed ID: 30288940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
